Long-Term Physical Activity Effectively Reduces the Consumption of Antihypertensive Drugs: A Randomized Controlled Trial.
antihypertensive drug load
blood pressure
exercise
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
03 Jul 2023
03 Jul 2023
Historique:
received:
04
06
2023
revised:
28
06
2023
accepted:
01
07
2023
medline:
28
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Although physical activity (PA) has been shown to enhance hypertension control, the impact of exercise on the potential decrease of the use of antihypertensive medications remains inadequately researched. The aim was to assess the impact of a two-year PA on the medication requirements of individuals with hypertension. A clinical trial was conducted, involving 130 participants with essential hypertension who took at least one antihypertensive medication. Participants were randomly assigned to either a control group (CG A total of 76 participants completed the 24-month assessment, and RM-ANOVA revealed a significantly lower antihypertensive drug load in the EG compared to the CG at 18 ( A long-term PA program can decrease the antihypertensive drug load in older adults with essential hypertension. The trend of improvement regarding the EG drug load intake and the trend of CG drug load increase, although not significant over time, results in a significant difference between the groups at 18 months and an even greater difference at 24 months. This trend certifies the protective value of PA against the aging process and its related health risk factors.
Sections du résumé
BACKGROUND
BACKGROUND
Although physical activity (PA) has been shown to enhance hypertension control, the impact of exercise on the potential decrease of the use of antihypertensive medications remains inadequately researched.
AIM
OBJECTIVE
The aim was to assess the impact of a two-year PA on the medication requirements of individuals with hypertension.
METHODS
METHODS
A clinical trial was conducted, involving 130 participants with essential hypertension who took at least one antihypertensive medication. Participants were randomly assigned to either a control group (CG
RESULTS
RESULTS
A total of 76 participants completed the 24-month assessment, and RM-ANOVA revealed a significantly lower antihypertensive drug load in the EG compared to the CG at 18 (
CONCLUSION
CONCLUSIONS
A long-term PA program can decrease the antihypertensive drug load in older adults with essential hypertension. The trend of improvement regarding the EG drug load intake and the trend of CG drug load increase, although not significant over time, results in a significant difference between the groups at 18 months and an even greater difference at 24 months. This trend certifies the protective value of PA against the aging process and its related health risk factors.
Identifiants
pubmed: 37504541
pii: jcdd10070285
doi: 10.3390/jcdd10070285
pmc: PMC10380464
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
J Am Coll Cardiol. 2018 Sep 11;72(11):1278-1293
pubmed: 30190007
J Am Heart Assoc. 2013 Feb 01;2(1):e004473
pubmed: 23525435
Front Cardiovasc Med. 2022 Jan 21;8:770975
pubmed: 35127851
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
J Aging Phys Act. 2017 Oct 1;25(4):612-620
pubmed: 28290764
J Clin Med. 2023 Jan 17;12(3):
pubmed: 36769399
Healthcare (Basel). 2022 Jul 11;10(7):
pubmed: 35885810
J Hypertens. 2013 Oct;31(10):1925-38
pubmed: 24107724
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
J Strength Cond Res. 2018 Apr;32(4):1072-1080
pubmed: 29570598
Eur Heart J. 2012 Jul;33(13):1635-701
pubmed: 22555213
J Hum Hypertens. 2017 Mar;31(3):157-164
pubmed: 27604656
Br J Sports Med. 2019 Jul;53(14):859-869
pubmed: 30563873
Respir Care. 2003 Aug;48(8):783-5
pubmed: 12890299
J Hypertens. 2021 Aug 1;39(8):1522-1545
pubmed: 34102660
Expert Rev Cardiovasc Ther. 2020 Feb;18(2):117-125
pubmed: 32066287
Hypertens Res. 2022 Aug;45(8):1392-1397
pubmed: 35672455
Br J Sports Med. 2015 Jun;49(11):710-5
pubmed: 25601182
Exerc Sport Sci Rev. 2008 Oct;36(4):173-8
pubmed: 18815485
J Clin Epidemiol. 1993 Feb;46(2):153-62
pubmed: 8437031
Nutrients. 2022 Jun 17;14(12):
pubmed: 35745256
Life (Basel). 2020 Aug 17;10(8):
pubmed: 32824416
Int J Environ Res Public Health. 2012 Feb;9(2):391-407
pubmed: 22470299
BMC Cardiovasc Disord. 2016 Nov 3;16(1):208
pubmed: 27809779
JAMA Cardiol. 2022 May 1;7(5):571-572
pubmed: 35262631
Am J Med. 2002 Apr 1;112(5):343-7
pubmed: 11904107
J Hypertens. 2020 Dec;38(12):2501-2509
pubmed: 32694343
Front Aging Neurosci. 2023 Feb 09;15:1086487
pubmed: 36845654
Am J Cardiol. 1989 Aug 1;64(5):348-53
pubmed: 2756880
Can J Cardiol. 2018 Dec;34(12):1641-1647
pubmed: 30527153
J Funct Morphol Kinesiol. 2021 Jun 14;6(2):
pubmed: 34198610
Eur J Prev Cardiol. 2023 Jan 11;30(1):17-33
pubmed: 35947982
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
JAMA. 2018 Nov 20;320(19):2020-2028
pubmed: 30418471
Trends Endocrinol Metab. 2020 Aug;31(8):561-569
pubmed: 32284283
Scand J Rehabil Med. 1970;2(2):92-8
pubmed: 5523831
Hypertension. 2022 Jul;79(7):1487-1496
pubmed: 35574838
Eur J Prev Cardiol. 2023 Jan 11;30(1):95-97
pubmed: 36097372
Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96
pubmed: 27353126
Clin Interv Aging. 2018 Apr 09;13:541-553
pubmed: 29674845
Prog Cardiovasc Dis. 2016 Nov - Dec;59(3):226-234
pubmed: 27697533
Prev Med. 2015 Mar;72:34-43
pubmed: 25579505